Total Tracker – Christmas Eve Premarket: CTXR, INDP, RPTX, SIDU
December 24, 2025 – short Christmas Eve session, thin liquidity, biotech microcaps in movimento.
1. Market backdrop – Christmas Eve mood
Wall Street comes into Christmas Eve with the S&P 500 at fresh record highs after several strong sessions driven mainly by mega-cap tech. Today’s session is shortened, volumes are thin and the mood is a mix of “Santa Claus rally” and “better not break anything before the holidays”.
Index futures in the premarket are slightly red, just a few basis points, with traders digesting a very strong Q3 GDP print but softer consumer confidence and flat factory output. Cuts are still priced in for 2026, but nobody vuole fare l’eroe in una mattinata come questa.
Outside the US, European markets are mixed to slightly lower and several exchanges close early. Asia trades cautiously: the macro picture is good, but with liquidity this thin, a modest order flow is enough to send small caps flying.
In other words: the backdrop is benign, but microcaps + Christmas Eve + newsflow = volatility squared.
2. CTXR – Citius / Citius Oncology: LYMPHIR finally in the wild
commercial launch + fragile balance sheet
What’s new
Citius Pharmaceuticals and its controlled company Citius Oncology have just reported their FY 2025 results and business update, and confirmed the US commercial launch of LYMPHIR, a targeted immunotherapy for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL) stage I–III after at least one prior systemic therapy.
A few key points from the latest numbers and press releases:
- LYMPHIR was launched in the US in December 2025 via Citius Oncology.
- Citius Pharma owns roughly three quarters of Citius Oncology, keeping economic exposure concentrated.
- Net loss FY 2025 remains close to the prior year, around the high-30M US$ range.
- Cash on hand is only a few million dollars, which is extremely tight for an oncology commercial launch.
- Citius Oncology has already raised fresh capital through a December financing to support LYMPHIR’s ramp.
How the market is reading it
- Bullish angle: after years of development, there is finally a cancer product on the market, not just clinical slides. For microcap biotech traders, “commercial” is a magic word.
- Bearish angle: the balance sheet is thin, there are manufacturing and launch commitments, and more capital will likely be needed unless uptake is very strong and very fast.
On social channels you see the usual split: some celebrate the launch as the start of a new chapter, others point straight at the cash line and talk about future dilution risk. On a Christmas Eve premarket, that mix is exactly what can fuel big percentage swings even on modest news.
3. INDP – Indaptus Therapeutics: the “David Lazar trade”
new money, new boss, huge potential dilution
Deal structure in plain English
Indaptus has announced a transformative deal with investor David E. Lazar:
- 6 M US$ raised via private sale of Series AA and Series AAA Convertible Preferred.
- Preferred are sold at 6 US$ per share and are ultimately convertible into about 111 million common shares, subject to shareholder approval.
- These preferred shares sit senior to common in a liquidation waterfall.
- Lazar also agrees to acquire common stock and to become co-CEO and Chairman of the company.
In practice this is an almost complete reset of the capital structure and control of Indaptus.
Why premarket traders care
For a tiny clinical-stage biotech, 6 M US$ can be the difference between running out of runway in a few quarters and having time to push a lead program further. But the price is high: if fully converted, the preferred could turn into a common share count that dwarfs today’s float.
- Optimists see Lazar as a specialist in turning around microcaps and giving them a second life, even at the cost of heavy dilution.
- Pessimists see the 111M potential shares, compare that to current ownership, and conclude that existing holders risk being squeezed into irrelevance unless something very positive happens clinically.
In premarket, the stock has been swinging hard as the market tries to price the trade: how much of the “Lazar effect” is real upside, and how much is just year-end speculative energy on a thin tape.
4. RPTX – Repare Therapeutics: M&A story plus Polθ sale to Gilead
event-driven, not a classic biotech trade anymore
The bigger picture: being acquired
Repare is already in the middle of a strategic transaction: the company has agreed to be acquired by XenoTherapeutics. Under the announced terms, shareholders are expected to receive a cash payment per share plus a non-transferable contingent value right (CVR) that could pay out over time based on monetization of Repare’s partnered assets.
A shareholder vote is scheduled for mid-January 2026 and closing is targeted for the first quarter of 2026, subject to approvals and usual conditions.
Today’s twist: RP-3467 goes to Gilead
This morning Repare announced a definitive asset purchase agreement with Gilead Sciences:
- Gilead will acquire Repare’s Polθ ATPase inhibitor RP-3467.
- Total consideration is “up to 30 M US$” with a 25 M US$ upfront plus 5 M US$ tied to tech transfer milestones.
- This is the third and most significant portfolio deal Repare has signed this year on non-core assets.
The message from management is clear: convert R&D assets into cash, strengthen the balance sheet and make the deal with XenoTherapeutics easier to close – and potentially more attractive in absolute cash per share terms.
How traders frame it
- Arb funds look almost exclusively at the spread: current price vs. expected cash + optionality from the CVR.
- Fundamental biotech investors are increasingly out of the picture here: the story is now mostly legal, deal-related and cash-distribution driven.
For a Christmas Eve premarket, RPTX behaves much more like a special situation / arbitrage play than a pipeline stock: news like the Gilead deal moves the “cash math”, not the classic risk-reward around clinical data.
5. SIDU – Sidus Space: SHIELD contract and the inevitable offering
defence IDIQ + space microcap funding reality
First act: SHIELD IDIQ headline
On December 22, Sidus Space announced it has been selected as one of the awardees under the Missile Defense Agency’s SHIELD IDIQ program, a long-term contract vehicle with a ceiling of 151 B US$ shared among multiple companies. The focus: technologies for layered homeland defence, including AI/ML, space-based sensing and open architectures.
The market, come sempre, ha letto solo i primi due elementi: “space” e “151 B$”. Intra-day, SIDU has printed very aggressive percentage moves as retail traders projected huge revenue streams onto what is, in reality, an eligibility to compete for task orders inside a gigantic framework.
Second act: the 25 M US$ equity raise
Shortly after the contract excitement, Sidus announced a public offering of about 19.2 M shares at 1.30 US$ per share, for roughly 25 M US$ in gross proceeds. The pricing came at a discount vs. the spike levels, and the stock reacted with a sharp gap-down in premarket.
From a balance-sheet perspective, the move is understandable: Q3 numbers showed pressure on revenue and a meaningful cash burn, and serious participation in SHIELD-type work requires capital. From a trading perspective, però, il copione è il classico:
- Big contract headline → spike → equity offering → hangover.
Retail sentiment is now split between:
- who sees the SHIELD positioning as a genuine step-up in credibility for Sidus in defence/space,
- and who sees only another microcap that uses every rally to refill the cash tank.
6. Quick wrap-up for fast readers
- CTXR: first real commercial product (LYMPHIR in CTCL) but with a very tight cash position and ongoing funding needs. Classic tension between “commercial” label and balance-sheet risk.
- INDP: David Lazar steps in with 6 M US$, preferred shares that could convert into ~111M common shares, and a leadership role. Turnaround potential vs. heavy dilution.
- RPTX: no longer a pure pipeline story; behaves like an event-driven trade around an M&A deal and new cash from the Gilead Polθ transaction.
- SIDU: contract award on a huge defence IDIQ, followed almost immediately by a sizeable equity offering. Space/defence optionality vs. funding reality.
It’s Christmas Eve, volumes are thin, and the line between “smart speculative positioning” and “year-end FOMO” is even thinner. For anyone following these names, today is more about understanding the story than about forcing a trade.
HIGH-RISK DATA – ALWAYS VERIFY AT SOURCE
Dates, catalyst descriptions, deal terms and numbers mentioned above are based on public sources and can be
wrong, incomplete, delayed or already outdated.
Biotech and space/defence timelines move quickly (delays, amendments, new filings, updated guidance).
Before acting on any specific event, always re-check it directly on:
company press releases, SEC filings, FDA / regulator pages, official trial registries or defence-contract announcements.
This article is for informational and editorial purposes only. It is not investment advice, does not
contain buy/sell recommendations and does not take into account any individual’s objectives or constraints.
Notes based on public information available as of December 24, 2025, premarket. Market conditions, prices and sentiment may have changed by the time you read this.